Bio Techne Corp Stock Alpha and Beta Analysis
| TECH Stock | USD 57.92 2.61 4.72% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bio Techne Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bio Techne over a specified time horizon. Remember, high Bio Techne's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bio Techne's market risk premium analysis include:
Beta 1.86 | Alpha (0.14) | Risk 2.68 | Sharpe Ratio 0.0731 | Expected Return 0.2 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Bio Techne Backtesting, Bio Techne Valuation, Bio Techne Correlation, Bio Techne Hype Analysis, Bio Techne Volatility, Bio Techne History and analyze Bio Techne Performance. Bio Techne Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bio Techne market risk premium is the additional return an investor will receive from holding Bio Techne long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bio Techne. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bio Techne's performance over market.| α | -0.14 | β | 1.86 |
Bio Techne expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bio Techne's Buy-and-hold return. Our buy-and-hold chart shows how Bio Techne performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bio Techne Market Price Analysis
Market price analysis indicators help investors to evaluate how Bio Techne stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bio Techne shares will generate the highest return on investment. By understating and applying Bio Techne stock market price indicators, traders can identify Bio Techne position entry and exit signals to maximize returns.
Bio Techne Return and Market Media
The median price of Bio Techne for the period between Fri, Apr 25, 2025 and Thu, Jul 24, 2025 is 50.16 with a coefficient of variation of 3.92. The daily time series for the period is distributed with a sample standard deviation of 1.98, arithmetic mean of 50.4, and mean deviation of 1.61. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Cresset Asset Management LLC Has 13.68 Million Stock Holdings in Bio-Techne Co. | 05/07/2025 |
2 | Bio-Techne Co. Shares Bought by State of Wyoming | 05/19/2025 |
| Bio Techne dividend paid on 30th of May 2025 | 05/30/2025 |
3 | First Hawaiian Bank Buys 298 Shares of Bio-Techne Co. | 06/02/2025 |
4 | Disposition of 1280 shares by Herr Amy E. of Bio Techne at 44.33 subject to Rule 16b-3 | 06/09/2025 |
5 | Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development | 06/24/2025 |
6 | Lecap Asset Management Ltd. Buys Shares of 13,589 Bio-Techne Corp | 06/26/2025 |
7 | 1 SP 500 Stock to Research Further and 2 to Keep Off Your Radar | 07/03/2025 |
8 | Linden Thomas Advisory Services LLC Purchases 569 Shares of Bio-Techne Corp | 07/10/2025 |
9 | Bio-Technes Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy | 07/14/2025 |
10 | Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology | 07/15/2025 |
11 | INCY or TECH Which Is the Better Value Stock Right Now | 07/16/2025 |
12 | Bio-Techne Stock Is Up, What You Need To Know | 07/22/2025 |
About Bio Techne Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bio or other stocks. Alpha measures the amount that position in Bio Techne Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Dividend Yield | 0.003919 | 0.004464 | 0.005134 | 0.004877 | Price To Sales Ratio | 11.29 | 9.74 | 8.77 | 6.9 |
Bio Techne Upcoming Company Events
As portrayed in its financial statements, the presentation of Bio Techne's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bio Techne's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bio Techne's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bio Techne. Please utilize our Beneish M Score to check the likelihood of Bio Techne's management manipulating its earnings.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Build Portfolio with Bio Techne
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Bio Techne Backtesting, Bio Techne Valuation, Bio Techne Correlation, Bio Techne Hype Analysis, Bio Techne Volatility, Bio Techne History and analyze Bio Techne Performance. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Bio Techne technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.